论文部分内容阅读
目的 探析穿孔型胃癌采用新辅助化疗法治疗的临床效果.方法 选择2012G7-2013G7期间我院收治的穿孔型胃癌患者34例与外院共同收集病例30例为研究对象,根据电脑随机法分为两组,其中给予对照组常规D2根治术治疗,而观察组则运用新辅助化疗法治疗,对两组的治疗效果进行比较分析.结果 相比较对照组而言,观察组的肿瘤控制率较高,组间对比差异明显(P<005);与对照组相比,观察组的不良反应发生率低,组间比较有明显差异(P<005);同时,随访1-3年,两组1年、2年以及3年的生存率比较差异有统计学意义(P<005).结论 临床上给予穿孔型胃癌患者新辅助化疗法治疗,不仅可以提高肿瘤控制率,还能降低不良反应发生率,延长患者的生存时间.
Objective To investigate the clinical effect of neoadjuvant chemotherapy for perforation type gastric cancer.Methods 34 cases of perforation type gastric cancer admitted in our hospital during 2012G7-2013G7 and 30 cases co-collected by the outer hospital were selected as the research objects and divided into two groups according to computer randomization , Of which the control group received conventional D2 radical surgery, while the observation group was treated with neoadjuvant chemotherapy, the treatment effect of the two groups were compared.Results Compared with the control group, the observation group had a higher rate of tumor control group Compared with the control group, the incidence of adverse reactions in the observation group was low, there was a significant difference between the two groups (P <005); at the same time, follow-up 1-3 years, two groups of 1 year, (P <0.05) .Conclusion The neoadjuvant chemotherapy in patients with perforation type gastric cancer can not only improve the rate of tumor control, but also reduce the incidence of adverse reactions and prolong the rate of adverse reactions Patient’s survival time.